Peroneal and Achilles Tendon Repair Indications With CLARIX® CORD 1K (PATRICC)
A Multi-center, Open Label, Economic Outcome Study Comparing the Recovery of Patients Receiving CLARIX® CORD 1K as an add-on Treatment During Surgical Tendon Repair to Control Patients Receiving Standard of Care Procedures
Peroneal and Achilles tendon tears are common diseases that present challenges to surgeons due to tendon adhesion complications. Functional recovery is compromised by limiting post-operative range of motion, mobility, and can lead to considerable amount of post-operative pain for the patient.
Amniotic membrane tissue has demonstrated clinical success as an anti-inflammatory and anti-scarring agent and promoting wound healing towards regeneration.
Cryopreserved human amniotic membrane and umbilical cord (AM/UC) tissue in the form of CLARIX® CORD 1K has been used to treat over 5000 orthopedic patients. The investigators hypothesize that its use in peroneal and Achilles tendon surgical repair will enhance the overall functional recovery of the patient.
研究概览
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Arizona
-
Phoenix、Arizona、美国、85037
- Banner Estrella Medical Center
-
Sun City West、Arizona、美国、85375
- Banner Del Webb Medical Center
-
-
North Carolina
-
Charlotte、North Carolina、美国、28207
- OrthoCarolina Research Institute
-
-
Ohio
-
Westerville、Ohio、美国、43082
- Orthopedic Foot and Ankle Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male and female patients 18 years to 80 years of age
- Confirmed tendon pathology via MRI, if clinically necessary, with planned surgical repair that have failed conservative management (PT) for a minimum of 2 months for chronic and partial thickness tears; acute full thickness tears or tendon rupture immediately eligible.
- Willing to follow the instructions and complete the visits required.
Exclusion Criteria:
- Psychologically unstable
- Acute infections that, in the opinion of the investigator, may complicate healing
- Currently receiving chemotherapy
- Systemic inflammatory arthritis or Rheumatoid arthritis
- Uncontrolled diabetes as measured by A1C>12
- Bleeding disorders
- Unable to provide informed consent
- Has received oral or parenteral corticosteroids or cytotoxic agents for seven consecutive days in the period of 30 days before surgery OR has received a local steroid injection within 7 days of surgery
- Immunocompromised patients
- Active malignancy other than non-melanoma skin cancer
- Untreated alcohol or substance abuse issues at the time of screening
- Pregnant women at the time of randomization
- Currently enrolled or participated in another investigational device, drug, or biological trial within 60 days of screening
- Allergy to amphotericin-B or Dulbecco's Modified Eagle Medium (DMEM).
- Will undergo significant concurrent procedures with the tendon procedures on the affected foot that, in the opinion of the Investigator, may complicate healing or alter the post-operative visit schedule
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:CLARIX® CORD 1K
Applied in addition to standard of care tendon repair surgery.
|
|
无干预:Standard of care tendon repair surgery only
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Change from baseline in patient questionnaire describing function limitation (American Orthopaedic Foot and Ankle Society ankle hindfoot score).
大体时间:Baseline and 1 Year
|
Baseline and 1 Year
|
合作者和调查者
调查人员
- 学习椅:Scheffer Tseng, MD, PhD、Tissue Tech Inc.
出版物和有用的链接
一般刊物
- Gelberman RH, Manske PR. Factors influencing flexor tendon adhesions. Hand Clin. 1985 Feb;1(1):35-42.
- Adzick NS, Lorenz HP. Cells, matrix, growth factors, and the surgeon. The biology of scarless fetal wound repair. Ann Surg. 1994 Jul;220(1):10-8. doi: 10.1097/00000658-199407000-00003.
- Jaibaji M. Advances in the biology of zone II flexor tendon healing and adhesion formation. Ann Plast Surg. 2000 Jul;45(1):83-92. doi: 10.1097/00000637-200045010-00017.
- Liu J, Sheha H, Fu Y, Liang L, Tseng SC. Update on amniotic membrane transplantation. Expert Rev Ophthalmol. 2010 Oct;5(5):645-661. doi: 10.1586/eop.10.63.
- Swift H. Amnion for leg ulcers. Lancet. 1980 Jun 21;1(8182):1366-7. doi: 10.1016/s0140-6736(80)91819-x. No abstract available.
- Dua HS, Gomes JA, King AJ, Maharajan VS. The amniotic membrane in ophthalmology. Surv Ophthalmol. 2004 Jan-Feb;49(1):51-77. doi: 10.1016/j.survophthal.2003.10.004.
- Bouchard CS, John T. Amniotic membrane transplantation in the management of severe ocular surface disease: indications and outcomes. Ocul Surf. 2004 Jul;2(3):201-11. doi: 10.1016/s1542-0124(12)70062-9.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CR-2010
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
CLARIX® CORD 1K graft的临床试验
-
Johns Hopkins University撤销糖尿病足 | 糖尿病足溃疡 | 糖尿病足部感染 | 糖尿病足溃疡混合 | 血管性溃疡(动脉或静脉性溃疡,包括不在足部的糖尿病性溃疡)
-
The University of Texas Health Science Center,...招聘中
-
The University of Texas Health Science Center,...招聘中
-
University Hospital, Gentofte, CopenhagenB. Braun Melsungen AG完全的间歇性跛行 | 严重肢体缺血